A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial-Reference-Cited by-同舟云学术

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial

Published:2021-11-17 Issue:3 Volume:111 Page:595-604
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Chigutsa Emmanuel¹,Jordie Eric²,Riggs Matthew²,Nirula Ajay¹,Elmokadem Ahmed²,Knab Tim²,Chien Jenny Y.¹

Affiliation:

1. Eli Lilly and Company Indianapolis Indiana USA

2. Metrum Research Group, Inc. Tariffville Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2459

Reference37 articles.

1. An interactive web-based dashboard to track COVID-19 in real time

2. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

3. A new coronavirus associated with human respiratory disease in China

4. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

5. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity;Clinical Pharmacokinetics;2024-09-03

2. Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics;Vaccines;2024-07-16

3. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness;Antimicrobial Agents and Chemotherapy;2024-04-03

4. Sample-efficient Antibody Design through Protein Language Model for Risk-aware Batch Bayesian Optimization;2023-11-08

5. Cell-based passive immunization for protection against SARS-CoV-2 infection;Stem Cell Research & Therapy;2023-11-06